Hepatic steatosis rather than visceral adiposity is more closely associated with insulin resistance in the early stage of obesity.
The aim of the present study was to investigate the specific relationship between hepatic steatosis and insulin resistance in the early stage of obesity. Among general health examinees who received an ultrasound scanning, 131 subjects without fatty liver (non-FL group) and 142 subjects with fatty liver (FL group) were selected so that both groups were matched for age, sex, body mass index, and % body fat. The FL group was then subdivided into 2 groups according to the severity of steatosis by ultrasound. Insulin resistance was assessed by homeostasis model assessment for insulin resistance, serum high-molecular-weight (HMW) adiponectin, and insulin-like growth factor binding protein 1 concentrations. Unexpectedly, the non-FL group showed higher waist circumference than the FL group. Nevertheless, homeostasis model assessment for insulin resistance as well as conventional insulin resistance indexes such as serum insulin, free fatty acid, and triglyceride levels demonstrated a stepwise increase, and HMW adiponectin and insulin-like growth factor binding protein 1 demonstrated a stepwise decrease with increasing degree of hepatic steatosis. Overall, insulin resistance markers correlated with obesity indexes, but only HMW adiponectin no longer showed any meaningful correlation in the presence of fatty liver. The prevalence of BP, fasting serum glucose, and high-density lipoprotein cholesterol above or below cutoff points and subjects having 2 or more metabolic syndrome components were higher in the moderate to severe FL group compared to the non-FL group. In conclusion, these results in nondiabetic and relatively normal-body mass index subjects suggest that hepatic steatosis is independently associated with insulin resistance regardless of extrahepatic adiposity and might be the earliest event in pathogenesis of the metabolic syndrome.
The Internal Medicine, Saitama-ken Saiseikai Kurihashi Hospital, Saitama-ken 349-1105, Japan. tounyo@saikuri.org
Taro
T
Wasada
Takayuki
T
Kasahara
Junko
J
Wada
Sachiyo
S
Jimba
Risa
R
Fujimaki
Tomoko
T
Nakagami
Yasuhiko
Y
Iwamoto
D052242:Adiponectin / Q000097:blood; D050154:Adiposity / Q000502:physiology*; D015415:Biomarkers; D015992:Body Mass Index; D008076:Cholesterol, HDL / Q000097:blood; D005234:Fatty Liver / Q000000981:diagnostic imaging / Q000378:metabolism*; D005260:Female; D006801:Humans; D007333:Insulin Resistance / Q000502:physiology*; D018970:Insulin-Like Growth Factor Binding Protein 1 / Q000097:blood; D008297:Male; D024821:Metabolic Syndrome / Q000378:metabolism; D008875:Middle Aged; D009765:Obesity / Q000000981:diagnostic imaging / Q000378:metabolism*; D014463:Ultrasonography; D049629:Waist-Hip Ratio
D052242:Adiponectin; D015415:Biomarkers; D008076:Cholesterol, HDL; D018970:Insulin-Like Growth Factor Binding Protein 1